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As a whole, these studies indicate that
the FX is the major mediator of liver tro-
pism of Ad5 through binding to the hexon
protein. These results have important
implications for the design of safer adeno-
virus vectors. Simply swapping the fiber
protein of Ad5 with that of another sero-
type will not prevent the virus from infect-
ing the liver. Similarly, attempts to modify
the fiber to retarget it to receptors other
than CAR will likely need to be coupled
with changes to the hexon. Ad26, one vi-
rus that does not bind FX, is already under
development as a vector. In addition, Os-
tapchuk and Hearing (2001) have demon-
strated that one can produce Ad5-based
vectors that incorporate hexons from
other serotypes. The stage is set, then,
for approaches that will improve the
safety of adenovirus as a therapeutic tool.
REFERENCES
McCoy, R.D., Davidson, B.L., Roessler, B.J.,
Huffnagle, G.B., Janich, S.L., Laing, T.J., and
Simon, R.H. (1995). Hum. Gene Ther. 6, 1553–
1560.
Nicklin, S.A., Wu, E., Nemerow, G.R., and Baker,
A.H. (2005). Mol. Ther. 12, 384–393.
Ostapchuk, P., and Hearing, P. (2001). J. Virol. 75,
45–51.
Parker, A.L., Waddington, S.N., Nicol, C.G.,
Shayakhmetov, D.M., Buckley, S.M., Denby, L.,
Kemball-Cook, G., Ni, S., Lieber, A., McVey, J.H.,
et al. (2006). Blood 108, 2554–2561.
Raper, S.E., Chirmule, N., Lee, F.S., Wivel, N.A.,
Bagg, A., Gao, G.P., Wilson, J.M., and Batshaw,
M.L. (2003). Mol. Genet. Metab. 80, 148–158.
Shayakhmetov, D.M., Gaggar, A., Ni, S., Li, Z.Y.,
and Lieber, A. (2005). J. Virol. 79, 7478–7491.
Waddington, S.N., Parker, A.L., Havenga, M.,
Nicklin, S.A., Buckley, S.M., McVey, J.H., and
Baker, A.H. (2007). J. Virol. 81, 9568–9571.
Waddington, S.N., McVey, J.H., Bhella, D., Parker,
A.L., Barker, K., Atoda, H., Pink, R., Buckley,
S.M.K., Greig, J.A., Denby, L., et al. (2008). Cell
132, 397–409.
Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E.,
Gonczol, E., and Wilson, J.M. (1994). Proc. Natl.
Acad. Sci. USA 91, 4407–4411.
Figure 1. Two Ways for Adenovirus to Interact with Liver Cells
The surface of a liver cell is shown along with two bound adenovirus particles. The particle on the left con-
tacts the cell through a fiber knob-CAR interaction. That on the right contacts the cell through an interac-
tion between the hexons and FX, which is depicted as a bridge. The cellular receptor for this interaction is
not yet known. Illustration by Payam Entezami.
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In tailed bacteriophages and herpesviruses, double-stranded DNA is packaged into a pre-existing protein
shell, through a dedicated channel known as the portal. In a recent issue of Molecular Cell, Zheng et al. de-
termined the structure of the bacteriophage P22 portal complex in pre- and postpackaging conformations,
identifying structural changes that serve to retain the genome within the virus particle and prime it for injec-
tion into a new host.Tailed bacteriophages (caudovirales) rep-
resent over 90% of all known viruses of
prokaryotes and are arguably the most
abundant organisms on Earth. Moreover,
it is now clear that they share common120 Cell Host & Microbe 3, March 2008 ª20ancestry with Herpesviruses, which are
ubiquitous pathogens in vertebrates, and
it seems likely that an undiscovered gal-
axy of related forms infect other eukary-
otes. It is reasonable to assume, there-08 Elsevier Inc.fore, that viruses of the caudovirales
lineage are doing something right, and
one of their strengths seems to lie in their
particle assembly and DNA-packaging
mechanisms.
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genome achieves its aim of spreading be-
tween hosts. To shield the genome from
the extracellular environment, it is en-
closed in a structure called the capsid:
a self-assembling machine that actively
packages the DNA, protects it, and
delivers it in functional form. Particle as-
sembly in typical tailed bacteriophages is
a dynamic process in which protein sub-
components interact to form an initial,
weak structure (the procapsid) that,
through a process of mutual folding and
rearrangement, undergoes an irreversible
phase change to adopt a rigid, durable
conformation (the mature capsid). The
transition is triggered by DNA packaging
and represents one of the most complex
molecular processes yet analyzed. As
theDNAenters through adedicated struc-
ture called the portal, internal proteins are
expelled through pores in the capsid shell;
the remaining capsid proteins undergo
large-scale reconfigurations, expanding
the particle and forming a continuous
closed shell. In the process, new interac-
tions are formed that strengthen the struc-
ture. Finally, when DNA packaging is
completed, the tail assembly is added to
the portal, preparing the particle for the
next round of infection.
An integral component of thismolecular
machinery is the packaging motor formed
by the portal and the associated DNA
translocation and cleavage complex (the
terminase). This occupies a site of five-
fold symmetry on the capsid shell (John-
son and Chiu, 2007). The portal is in the
form of a ring with a channel through the
center to allowDNA transit. All known por-
tals are homo-dodecamers, although the
reason for this is not clear. In one packag-
ing model, a rotating portal was envis-
aged as winding the DNA helix into the
capsid, and it was suggested that the
12:5 symmetry mismatch between portal
and capsid prevents the portal from be-
coming locked into a preferred orienta-
tion. Attractive though this model is,
recent experiments appear to have ruled
out portal rotation during packaging (Hu-
gel et al., 2007), obliging us to find another
explanation for its distinctive shape. The
DNA inside a virus particle is compacted
to near crystalline density and exerts
tremendous outward pressure on the
capsid. To package DNA against this
pressure requires considerable effort,
and the portal-terminase motor is one ofFigure 1. Reconfiguration of the P22 Portal following gp4 Binding
Schematic diagram of portals in the procapsid (A) and mature capsid (B) forms. The dotted orange lines
indicate the approximate position of the capsid shell, with the top of the portal on the inside and the
exposed end at the bottom. The viral DNA (gray cylinders) is packaged into the procapsid by the por-
tal-terminase. When the capsid is full, the terminase (magenta) is replaced by the accessory protein
gp4 (dark blue). The 12 portal proteins reconfigure (illustrated by the reorientation of the blue ellipses)
and form a new DNA-binding domain that holds the end of the DNA ready for injection back through
the portal channel upon infection of a new host. The arrows show the direction of DNA movement during
packaging (A) and injection (B).strongest molecular engines known
(Smith et al., 2001). However, the role of
the portal alters during maturation, and
once packaging ends the channel has to
be blocked to prevent premature release
of the DNA. The major part in closing the
channel is probably played by compo-
nents associated with the tail (Chang
et al., 2006; Jiang et al., 2006; Lander
et al., 2006; Orlova et al., 2003), but
changes in the structure of the portal de-
scribed for phages T7 and f29 suggest
that it may also contribute to this process
(Agirrezabala et al., 2005; Xiang et al.,
2006).
In their recent paper, Zheng et al. (2008)
use electron cryomicroscopy to examine
the bacteriophage P22 portal. They pres-
ent structures for the purified portal and
for a complex between the portal and
the accessory protein, gp4. At the com-
pletion of DNA packaging, the terminase
is released from the exposed end of the
portal and replaced by gp4 in a step that
prevents loss of DNA from the capsid.
Zheng et al. (2008) now report that binding
of gp4 to the isolated portal induces large-
scale conformational changes (Figure 1).
Their structure of the portal-gp4 complex
fits very well with that found in matureCell Host & Microcapsids (Chang et al., 2006; Lander
et al., 2006), and although the structure
of the portal in the procapsid has not
been determined, it is thought to resem-
ble that of the purified portal. Zheng
et al. (2008) therefore propose that the
conformational changes that they de-
scribe reproduce those occurring during
capsid maturation.
The changes induced by gp4 affect the
entire portal, but the most dramatic is the
appearance of a large, previously unre-
solved domain at its inner end (Figure 1).
In their reconstructions, it appears as
a solid lens that obscures the portal chan-
nel, but in the intact phage this density,
which has previously been ascribed to
an internal pilot protein, is ring shaped
(Chang et al., 2006; Lander et al., 2006).
Zheng et al. (2008) demonstrate that this
domain binds double-stranded DNA,
and they propose that the domain is
formed when disordered regions of the
portal proteins containing DNA-binding
motifs coalesce to form a ring of 12 alpha
helices with their DNA-binding faces lining
the channel. An obvious conclusion is that
the newly formed domain holds the pack-
aged DNA in the capsid until the addition
of the tail completes the process ofbe 3, March 2008 ª2008 Elsevier Inc. 121
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Previewssealing the portal channel. Another role is
suggested by the difficulty in imagining
how tightly packaged DNA can be un-
wound from inside a capsid without be-
coming tangled. DNA is packaged by
a last-in, first-out process, and the termi-
nal sequences of several phage genomes
are known to be retained within the portal
channel (Agirrezabala et al., 2005; Jiang
et al., 2006; Lander et al., 2006; Xiang
et al., 2006). Thus, by holding on to the
end of the DNA, the portal may preposi-
tion it for efficient ejection. Zheng et al.
(2008) comment that in this way the con-
formational changes in the portal ‘‘directly
couple completion of virus morphogene-
sis to a new cycle of infection.’’
One interesting aspect of this study is
the demonstration that gp4 binding alone
can induce portal reconfiguration. This
appears to conflict with suggestions that
conformational changes in the portal
result from pressure exerted by the
fully packaged DNA (Agirrezabala et al.,
2005; Lander et al., 2006) and trigger sub-
sequent maturation steps including, in
P22, replacement of the terminase by
gp4. Given the sequence of events re-A New Antitubercu
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An important report by Bryk et al. in
prodrug active against nonmultiplyi
replicating Mtb to most currently av
losis arsenal and would greatly ben
While effective vaccination to eliminate
latent tuberculosis (TB) is still distant, the
main avenue for its control is case finding
and treatment. Current treatment proto-
cols are lengthy, involving 6 months dur-
ing which it is only too easy for patients
to fail to continue regular drug taking.
Present efforts in improving treatment fo-
cus on shortening the length of treatment.
122 Cell Host & Microbe 3, March 2008 ª20quired to form a complete particle, it
seems probable that portal reconfigura-
tion does indeed precede gp4 binding
and that the situation seen here is a reflec-
tion of the altered environment occupied
by the portal when unconstrained by the
capsid.
Their combination of compositional
simplicity and functional complexity
makes bacteriophages objects of fascina-
tion to biologists, and this paper con-
tributes to our increasingly detailed
knowledge of these remarkable entities.
Nevertheless, as we continue to probe
their sophistication, the limitations of our
understanding remain apparent. Thus,
while snapshots of beginning and end
states create space for intellectual inven-
tion, we are still a long way from uncover-
ing the true nature of the molecular transi-
tions they reveal and of the forces that
drive them.
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cribes the properties of a rhodanine
). Considering the tolerance of non-
a major addition to our antitubercu-
highly susceptible bacterial population in
an actively growing culture and the toler-
ant populations that are presumed to exist
in lesions in vivo. Phenotypic bacterial
tolerance is distinct from genetic drug
resistance since tolerant bacilli that revert
to rapid growth are susceptible to active
killing as usual. Therefore, it is vitally
important that drugs are developed to
